Synopsis
Synopsis
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Clopidogrel
2. Clopidogrel Besilate
3. Clopidogrel Besylate
4. Clopidogrel Hydrochloride
5. Clopidogrel Mepha
6. Clopidogrel Napadisilate
7. Clopidogrel Sandoz
8. Clopidogrel, (+)(s)-isomer
9. Clopidogrel-mepha
10. Iscover
11. Pcr 4099
12. Pcr-4099
13. Plavix
14. Sc 25989c
15. Sc 25990c
16. Sr 25989
1. 120202-66-6
2. Clopidogrel Sulfate
3. Clopidogrel Hydrogen Sulfate
4. Iscover
5. Plavix
6. Clopidogrel Bisulphate
7. Clopidogrel Hemisulfate
8. (s)-methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate Sulfate
9. Clopidogrel Hydrogen Sulphate
10. Clopidogrel Bms
11. Clopidogrel Sulphate
12. Sr 25990c
13. Clopidogrel (hydrogen Sulfate)
14. Isocover
15. Pidogrel
16. Clopidogrel-bgr
17. Clopidogrel-bms
18. Clopidogrel Teva
19. Clopidogrel Zentiva
20. Clopidogrel (plavix)
21. Clopidogrel Ratiopharm
22. Sr-25990c
23. S-(+)-clopidogrel Hydrogen Sulfate
24. Clopidogrel (as Bisulfate)
25. (s)-(+)-clopidogrel Sulfate
26. 08i79htp27
27. 120202-66-6 (sulfate)
28. Pm-103
29. Methyl (s)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate Sulfate
30. 144077-07-6
31. Myogrel
32. Clopidogrel Hydrogensulfate
33. Plavix (tn)
34. Dsstox_cid_26024
35. Dsstox_rid_81297
36. Dsstox_gsid_46024
37. Plavitor
38. Osvix
39. Chebi:3759
40. Chembl1083385
41. Methyl (2s)-2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate Sulfate
42. Methyl (2s)-2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate;sulfuric Acid
43. Sulfuric Acid Methyl (2s)-2-(2-chlorophenyl)-2-{4h,5h,6h,7h-thieno[3,2-c]pyridin-5-yl}acetate
44. Clopidogrel Bisulfate [usan]
45. Cas-135046-48-9
46. Unii-08i79htp27
47. R-(-)-clopidogrel Hydrogen Sulfate
48. Clopidogrel Bisulfate [usan:usp]
49. Isocover (tn)
50. Clopidogrel Bisolfato
51. (s)-(+)-clopidogrel Hydrogen Sulfate
52. Bisulfato De Clopidogrel
53. Bissulfato De Clopidogrel
54. Ncgc00159321-02
55. (+)-clopidogrel Bisulfate
56. (+) Clopidogrel Bisulfate
57. Methyl Alphas-(2-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4h)-acetate Sulfate (1:1)
58. Clopidogrel Bisulfate (usp)
59. Clopidogrel Sulfate (jp17)
60. Schembl33556
61. Clopidogrel Hydrogen Sulphate
62. Spectrum1503710
63. Mdco-157
64. (+)-clopidogrel Hydrogen Sulfate
65. Clopidogrel Sulfate [jan]
66. Dtxsid601016080
67. Hms1922g16
68. Hms2093i13
69. Hms3884g15
70. Pharmakon1600-01503710
71. Amy40591
72. Clopidogrel Sulfate Tablets (jp17)
73. Tox21_111570
74. Ccg-39568
75. Clopidogrel Bisulfate [vandf]
76. Mfcd00876395
77. Nsc758613
78. S1415
79. Clopidogrel Bisulfate [mart.]
80. Akos015900408
81. Clopidogrel Bisulfate [usp-rs]
82. Clopidogrel Bisulfate [who-dd]
83. Tox21_111570_1
84. Ac-2135
85. Cs-1882
86. Dv-7314
87. Ks-1045
88. S65c842
89. Clopidogrel (as Hydrogen Sulfate)
90. Clopidogrel Hydrogen Sulfate [mi]
91. Ncgc00163329-03
92. 111ge004
93. Bc164326
94. Hy-17459
95. Methyl (+)-(s)-alpha-(o-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4h)-acetate, Sulfate (1:1)
96. Thieno(3,2-c)pyridine-5(4h)-acetic Acid, 6,7-dihydro-alpha-(2-chlorophenyl)-, Methyl Ester, (s)-, Sulfate
97. Thieno(3,2-c)pyridine-5(4h)-acetic Acid, Alpha-(2-chlorophenyl)-6,7-dihydro-, Methyl Ester, (alphas)-, Sulfate (1:1)
98. Thieno(3,2-c)pyridine-5(4h)-acetic Acid, Alpha-(2-chlorophenyl)-6,7-dihydro-, Methyl Ester, (s)-, Sulfate (1:1)
99. Thieno[3,2-c]pyridine-5(4h)-acetic Acid,a-(2-chlorophenyl)-6,7-dihydro-, Methyl Ester, (as)-, Sulfate (1:1)
100. Clopidogrel Bisulfate [orange Book]
101. Clopidogrel Bisulfate [usp Monograph]
102. Sw219457-1
103. Clopidogrel Hydrogen Sulfate [ema Epar]
104. D00769
105. Duocover Component Clopidogrel Bisulfate
106. Duoplavin Component Clopidogrel Bisulfate
107. Clopidogrel Hydrogen Sulphate [ema Epar]
108. Clopidogrel Bisulfate Component Of Duocover
109. Clopidogrel Bisulfate Component Of Duoplavin
110. Clopidogrel Hydrogen Sulfate [ep Monograph]
111. Sr-05000002068
112. J-006637
113. Sr-05000002068-1
114. (+)-clopidogrel1r(-)camphor-10-sulphonic Acid Salt
115. (s)-(+)-clopidogrel Hydrogensulfate, >=98% (hplc)
116. Q27888063
117. Z1550648767
118. (s)-(+)-clopidogrel Bisulfate;(s)-(+)-clopidogrel Hydrogen Sulfate
119. Clopidogrel Bisulfate, United States Pharmacopeia (usp) Reference Standard
120. Clopidogrel Hydrogen Sulfate, European Pharmacopoeia (ep) Reference Standard
121. Clopidogrel/acetylsalicyclic Acid Teva Component Clopidogrel Bisulfate
122. (s)-(+)-methyl (2-chlorophenyl)(6,7-dihydro-4h-thieno(3,2-c)pyrid-5-yl)acetate Bisulfate
123. Clopidogrel Bisulfate Component Of Clopidogrel/acetylsalicyclic Acid Teva
124. Clopidogrel Bisulfate, Pharmaceutical Secondary Standard; Certified Reference Material
125. Clopidogrel For System Suitability, European Pharmacopoeia (ep) Reference Standard
126. Methyl(s)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetatesulfate
127. (s)-(+)-methyl 2-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)-2-(2-chlorophenyl)acetate Hydrogen Sulfate
128. (s)-(2-chloro-phenyl)-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)-acetic Acid Methyl Ester Sulfuric Acid Salt
129. (s)-methyl-(2-chloro-phenyl)-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)-acetate H2so4
130. Methyl (+)-(s)-.alpha.-(o-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4h)-acetate, Sulfate (1:1)
131. Methyl (+)-(s)-.alpha.-(o-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4h)-acetate, Sulphate (1:1)
132. Methyl (2s)-2-(2-chlorophenyl)-2-{4h,5h,6h,7h-thieno[3,2-c]pyridin-5-yl}acetate; Sulfuric Acid
133. Methyl (s)-(+)-2-(2-chlorophenyl)-2-[6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl]acetate Sulfate
134. Thieno(3,2-c)pyridine-5(4h)-acetic Acid, .alpha.-(2-chlorophenyl)-6,7-dihydro-, Methyl Ester, (s)-, Sulfate (1:1)
135. Thieno(3,2-c)pyridine-5(4h)-acetic Acid, .alpha.-(2-chlorophenyl)-6,7-dihydro-, Methyl Ester, (s)-, Sulphate (1:1)
Molecular Weight | 419.9 g/mol |
---|---|
Molecular Formula | C16H18ClNO6S2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 4 |
Exact Mass | 419.0264073 g/mol |
Monoisotopic Mass | 419.0264073 g/mol |
Topological Polar Surface Area | 141 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 463 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Clopidogrel bisulfate |
Drug Label | Clopidogrel bisulfate USP is a thienopyridine class inhibitor of P2Y12 ADP platelet receptors. Chemically it is methyl (+)-(S)--(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)acetate sulfate (1:1). The molecular formula of clopidogrel bisul... |
Active Ingredient | Clopidogrel bisulfate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 300mg base; eq 75mg base |
Market Status | Prescription |
Company | Wockhardt; Mylan Pharms; Actavis Elizabeth; Teva Pharms; Macleods Pharms; Mutual Pharm; Gate Pharms; Teva; Apotex; Accord Hlthcare; Sciegen Pharms; Aurobindo Pharma; Torrent Pharms; Zydus Pharms Usa; Dr Reddys Labs; Sun Pharma Global; Roxane |
2 of 4 | |
---|---|
Drug Name | Plavix |
PubMed Health | Clopidogrel (By mouth) |
Drug Classes | Platelet Aggregation Inhibitor |
Drug Label | Plavix (clopidogrel bisulfate) is a thienopyridine class inhibitor of P2Y12 ADP platelet receptors. Chemically it is methyl (+)-(S)--(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate sulfate (1:1). The empirical formula of clopidogrel... |
Active Ingredient | Clopidogrel bisulfate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 75mg base; eq 300mg base |
Market Status | Prescription |
Company | Sanofi Aventis Us |
3 of 4 | |
---|---|
Drug Name | Clopidogrel bisulfate |
Drug Label | Clopidogrel bisulfate USP is a thienopyridine class inhibitor of P2Y12 ADP platelet receptors. Chemically it is methyl (+)-(S)--(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)acetate sulfate (1:1). The molecular formula of clopidogrel bisul... |
Active Ingredient | Clopidogrel bisulfate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 300mg base; eq 75mg base |
Market Status | Prescription |
Company | Wockhardt; Mylan Pharms; Actavis Elizabeth; Teva Pharms; Macleods Pharms; Mutual Pharm; Gate Pharms; Teva; Apotex; Accord Hlthcare; Sciegen Pharms; Aurobindo Pharma; Torrent Pharms; Zydus Pharms Usa; Dr Reddys Labs; Sun Pharma Global; Roxane |
4 of 4 | |
---|---|
Drug Name | Plavix |
PubMed Health | Clopidogrel (By mouth) |
Drug Classes | Platelet Aggregation Inhibitor |
Drug Label | Plavix (clopidogrel bisulfate) is a thienopyridine class inhibitor of P2Y12 ADP platelet receptors. Chemically it is methyl (+)-(S)--(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate sulfate (1:1). The empirical formula of clopidogrel... |
Active Ingredient | Clopidogrel bisulfate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 75mg base; eq 300mg base |
Market Status | Prescription |
Company | Sanofi Aventis Us |
Secondary prevention of atherothrombotic events Clopidogrel is indicated in:
- Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
- Adult patients suffering from acute coronary syndrome:
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation
In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
Secondary prevention of atherothrombotic events
Clopidogrel is indicated in:
- Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
- Adult patients suffering from acute coronary syndrome:
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
- Prevention of atherothrombotic and thromboembolic events in atrial fibrillation
In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
* Secondary prevention of atherothrombotic events:
Clopidogrel is indicated in:
- Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
- Adult patients suffering from acute coronary syndrome:
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)
Clopidogrel in combination with ASA is indicated in:
- Adult patients with moderate to high-risk TIA (ABCD2 score 4) or minor IS (NIHSS 3) within 24 hours of either the TIA or IS event.
* Prevention of atherothrombotic and thromboembolic events in atrial fibrillation:
In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
Prevention of atherothrombotic events Clopidogrel is indicated in:
Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
Prevention Secondary prevention of atherothrombotic events Clopidogrel is indicated in:
- Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
- Adult patients suffering from acute coronary syndrome:
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
- Prevention of atherothrombotic and thromboembolic events in atrial fibrillation:
- In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
* Secondary prevention of atherothrombotic events:
Clopidogrel is indicated in:
- adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;
- adult patients suffering from acute coronary syndrome:
- non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);
- ST-segment-elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
- In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)
Clopidogrel in combination with ASA is indicated in:
- Adult patients with moderate to high-risk TIA (ABCD2 score 4) or minor IS (NIHSS 3) within 24 hours of either the TIA or IS event.
* Prevention of atherothrombotic and thromboembolic events in atrial fibrillation:
In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
- patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
For further information please refer to section 5. 1.
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
- Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
- Patients suffering from acute coronary syndrome:
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
Purinergic P2Y Receptor Antagonists
Compounds that bind to and block the stimulation of PURINERGIC P2Y RECEPTORS. Included under this heading are antagonists for specific P2Y receptor subtypes. (See all compounds classified as Purinergic P2Y Receptor Antagonists.)
B01AC04
B01AC04
B01AC04
B01AC03
B01AC04
B01AC04
B01AC04
B01AC04
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Clinical Supply
Grade : Oral
Application : Empty Capsules
Excipient Details : DBcaps® capsules are developed with a tamper-evident design to specifically address the clinical trial challenges of testing without bias.
Pharmacopoeia Ref : Not Available
Technical Specs : Size # AAA- E
Ingredient(s) : Gelatin, Unspecified
Dosage Form : Capsule
Grade : Oral
Application : Vegetarian Capsules
Pharmacopoeia Ref : Certified Vegan, Non-GMO, Vege...
Technical Specs : Size # 0-1
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : HardGel
Grade : Oral
Application : Empty Capsules
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Gelatin, Unspecified
Dosage Form : Capsule
Grade : Oral
Application : Vegetarian Capsules
Pharmacopoeia Ref : Complies with relevant Europea...
Technical Specs : Water content – less than 6%; Size #0
Ingredient(s) : HPMC AS
Dosage Form : Capsule
Grade : Oral and Inhalation
Application : Vegetarian Capsules
Pharmacopoeia Ref : Certified Vegan, Non-GMO, Vege...
Technical Specs : "Water content – less than 9%, can be customized; Size # 00el - 4
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Inhalation
Grade : Inhalation
Application : Empty Capsules
Pharmacopoeia Ref : Certified Vegan, Non-GMO, Vege...
Technical Specs : Size # 00el - 4
Ingredient(s) : Gelatin, Unspecified
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Injectable / Parenteral
Grade : Oral, Parenteral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Capsule
Grade : Oral
Application : Fillers, Diluents & Binders
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Lubricants & Glidants
Dosage Form : Tablet
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : It is a natural pregelatinized maize starch that has been specially developed as a binder for wet granulation.
Dosage Form : Tablet
Grade : Not Available
Application : Disintegrants & Superdisintegrants
Excipient Details : Used as disintegrants, fillers and binders (once cooked) in nutraceutical and pharmaceutical dosage forms.
Dosage Form : Tablet
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : Helps to manufacture Oral Dosage and Nutraceutical forms by acting as a filler-binder while serving as a fibre source for your customers.
Pharmacopoeia Ref : EP/USP/JP
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : Its range offers a unique blend of exceptional physical and chemical stability and no hygroscopicity.
Dosage Form : Tablet
Grade : Not Available
Application : Fillers, Diluents & Binders
Dosage Form : Tablet
Grade : Not Available
Application : Disintegrants & Superdisintegrants
Excipient Details : It is a superdisintegrant that provides an efficient disintegration at low level of use
Dosage Form : Tablet
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : Used as disintegrants, fillers and binders (once cooked) in nutraceutical and pharmaceutical dosage forms.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Corn Starch, Colloidal Silica
Dosage Form : Capsule
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : It is a Co-Processed Lactose starch for filler/binder having strong disintegrant properties.
Dosage Form : Cream / Lotion / Ointment
Grade : Not Available
Application : Thickeners and Stabilizers
Excipient Details : A co-processed product used as a secondary stabilizer and suspension agent in semi-solides formulas.
Pharmacopoeia Ref : EP/USP/JP
Technical Specs : Not Available
Ingredient(s) : Colloidal Microcrystalline Cellulose
Dosage Form : Cream / Lotion / Ointment
Grade : Not Available
Application : Thickeners and Stabilizers
Excipient Details : A co-processed product used as a secondary stabilizer and suspension agent in semi-solides formulas.
Pharmacopoeia Ref : EP/USP/JP
Technical Specs : Not Available
Ingredient(s) : Colloidal Microcrystalline Cellulose
Excipients by Applications
Application : Fillers, Diluents & Binders, Taste Masking
Excipient Details : Mannitol is used as a filler, bulking agent and taste masking agent in ODT formulations such as tablets.
Dosage Form : Granule / Pellet, Tablet
Grade : Oral
Category : Fillers, Diluents & Binders, Granulation, Solubilizers
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Dosage Form : Capsule, Granule / Pellet, Tablet
Grade : Oral
Category : Fillers, Diluents & Binders, Lubricants & Glidants
Application : Co-Processed Excipients
Excipient Details : Mannitol is a co-processed excipient with superior compactibility, lower disintegration time, and hygroscopicity.
Dosage Form : Capsule, Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Solution, Tablet
Grade : Parenteral, Topical, Oral
Category : Fillers, Diluents & Binders, Film Formers & Plasticizers, Lubricants & Glidants, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Brand Name : Polyethylene Glycol 4000
Application : Fillers, Diluents & Binders, Film Formers & Plasticizers, Lubricants & Glidants, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Excipient Details : PEG 4000 is used as a thickener & suspending agent in suspension injections. It is also used as plasticizer, binder, lubricant & solubilizer.
Dosage Form : Injectable / Parenteral, Tablet
Grade : Parenteral, Oral
Category : Fillers, Diluents & Binders, Parenteral, Thickeners and Stabilizers
Dosage Form : Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Taste Masking
Application : Direct Compression
Excipient Details : DC SIM 100 is a directly compressible simethicone powder used for antacid and anti-gas tablets.
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Dosage Form : Tablet, Orodispersible Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Disintegrants & Superdisintegrants, Fillers, Diluents & Binders, Taste Masking
Application : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Disintegrants & Superdisintegrants, Fillers, Diluents & Binders, Taste Masking
Excipient Details : Advantol® 300 is a DC pharmaceutical excipient used to create soft chew or fast melt oral dosage forms through co-processing technology.
Dosage Form : Tablet, Orodispersible Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Application : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Excipient Details : Compressol® SM, co-processed polyol, is a DC excipient of mannitol & sorbitol with superior compactibility, low disintegration time & hygroscopicity.
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression, Disintegrants & Superdisintegrants
Brand Name : Mannogem Granular
Application : Chewable & Orodispersible Aids, Direct Compression, Disintegrants & Superdisintegrants
Excipient Details : Mannogem Granular has larger particles, offering a softer texture for chewable tablets and excellent flow, disintegration, and compression properties.
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression, Taste Masking
Application : Chewable & Orodispersible Aids, Direct Compression, Taste Masking
Excipient Details : MS90 is a directly compressible magnesium hydroxide with starch used for chewable tablets due to its smooth mouthfeel and creamy texture.
Pharmacopoeia Ref : NA
Technical Specs : PSD D50: 150-170 µm, Tapped Density: 0.80
Ingredient(s) : Magnesium Hydroxide Excipient
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Application : Chewable & Orodispersible Aids, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Excipient Details : CS90 is a directly compressible calcium carbonate with starch used for chewable tablets due to its smooth mouthfeel and creamy texture.
Pharmacopoeia Ref : NA
Technical Specs : PSD D50: 150-175 µm, Tapped Density: 0.85
Ingredient(s) : Calcium Carbonate Excipient
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Dosage Form : Granule / Pellet, Tablet
Grade : Oral
Category : Fillers, Diluents & Binders, Granulation, Solubilizers
Dosage Form : Capsule, Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Solution, Tablet
Grade : Parenteral, Topical, Oral
Category : Fillers, Diluents & Binders, Film Formers & Plasticizers, Lubricants & Glidants, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Brand Name : Polyethylene Glycol 4000
Application : Fillers, Diluents & Binders, Film Formers & Plasticizers, Lubricants & Glidants, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Excipient Details : PEG 4000 is used as a thickener & suspending agent in suspension injections. It is also used as plasticizer, binder, lubricant & solubilizer.
Dosage Form : Cream / Lotion / Ointment, Gel, Solution
Grade : Oral, Topical
Category : Emulsifying Agents, Solubilizers, Topical
Application : Emulsifying Agents, Solubilizers, Topical
Excipient Details : Hydrosol 50 is used as a solubilizer and emulsifying agent in oral and topical liquid and semi-solid dosage forms.
Pharmacopoeia Ref : USP/NF
Technical Specs : N/A
Ingredient(s) : Polyoxyl 40 Hydrogenated Castor Oil
Dosage Form : Capsule, Cream / Lotion / Ointment, Emulsion, Injectable / Parenteral, Tablet
Grade : Oral, Topical & Parenteral
Category : Emulsifying Agents, Parenteral, Solubilizers, Topical
Brand Name : PEG/Macrogol 4000
Application : Emulsifying Agents, Parenteral, Solubilizers, Topical
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Polyethylene Glycol 4000
Brand Name : AFFINISOL HPMC HME
Application : Solubilizers
Excipient Details : Solubility enhancement, Spray-Dried Dispersion (SDD), Hot Melt Extrusion (HME)
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Capsule, Emulsion, Softgel Capsule, Solution, Tablet, Topical Film
Grade : Not Available
Category : Film Formers & Plasticizers, Solubilizers, Topical
Application : Film Formers & Plasticizers, Solubilizers, Topical
Excipient Details : Liquid plasticizer with high ADI, hydrophilic solvent & humectant in emulsions, skin penetration enhancer in topical formulaitons.
Pharmacopoeia Ref : Ph. Eur., JP, FCC, USP
Technical Specs : Not Available
Ingredient(s) : Propylene Glycol
Brand Name : Microlex® Cr.PVD CL-110
Application : Disintegrants & Superdisintegrants, Solubilizers
Excipient Details : It facilitates to facilitate the dissolution of poorly API due to porous surface morphology.
Pharmacopoeia Ref : Not Available
Technical Specs : Also Available as Microlex® Cr.PVD CL-25, Microlex® Cr.PVD UCL-...
Ingredient(s) : Crospovidone
Dosage Form : Capsule, Orodispersible Tablet, Tablet
Grade : Oral
Category : Disintegrants & Superdisintegrants, Solubilizers, Thickeners and Stabilizers
Application : Disintegrants & Superdisintegrants, Solubilizers, Thickeners and Stabilizers
Excipient Details : Super disintegrate, solublity enhancer, Suspension stabilizer, Complexing agent, Low peroxide content, Long term stability
Pharmacopoeia Ref : Not Available
Technical Specs : Crospovidone (Type-A/B)- USP-NF / Ph. Eur. / BP / IP
Ingredient(s) : Crospovidone
Grade : Oral
Category : Coating Systems & Additives, Fillers, Diluents & Binders, Film Formers & Plasticizers, Solubilizers, Thickeners and Stabilizers
Application : Coating Systems & Additives, Fillers, Diluents & Binders, Film Formers & Plasticizers, Solubilizers, Thickeners and Stabilizers
Pharmacopoeia Ref : USP-NF, EP, BP, IP, JP, FCC
Technical Specs : PVP K-K-30/ K-17/ K19/ K25/ K90
Ingredient(s) : Povidone
Dosage Form : Capsule, Cream / Lotion / Ointment, Emulsion, Gel, Solution, Tablet
Grade : Not Available
Category : Solubilizers
Brand Name : Kollisolv PEG 400
Application : Solubilizers
Excipient Details : Liquid plasticizer, Solvent for oral and topical applications, Hydrophilic fill for solubilization of hydrophilic APIs.
Pharmacopoeia Ref : Ph. Eur., JP, FCC, USP
Technical Specs : Not Available
Ingredient(s) : Polyethylene Glycol 400
Application : Fillers, Diluents & Binders, Taste Masking
Excipient Details : Mannitol is used as a filler, bulking agent and taste masking agent in ODT formulations such as tablets.
Dosage Form : Capsule, Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Solution, Tablet
Grade : Parenteral, Topical, Oral
Category : Fillers, Diluents & Binders, Film Formers & Plasticizers, Lubricants & Glidants, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Brand Name : Polyethylene Glycol 4000
Application : Fillers, Diluents & Binders, Film Formers & Plasticizers, Lubricants & Glidants, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Excipient Details : PEG 4000 is used as a thickener & suspending agent in suspension injections. It is also used as plasticizer, binder, lubricant & solubilizer.
Dosage Form : Injectable / Parenteral, Tablet
Grade : Parenteral, Oral
Category : Fillers, Diluents & Binders, Parenteral, Thickeners and Stabilizers
Application : Co-Processed Excipients
Excipient Details : Mannitol is a co-processed excipient with superior compactibility, lower disintegration time, and hygroscopicity.
Dosage Form : Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Softgel Capsule, Softgels
Grade : Parenteral, Topical, Oral
Category : Fillers, Diluents & Binders, Film Formers & Plasticizers, Parenteral, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Brand Name : Polyethylene Glycol 400
Application : Fillers, Diluents & Binders, Film Formers & Plasticizers, Parenteral, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Excipient Details : PEG 400 is used as a suspending agent, stabilizer, plasticizer and filler in OSDs, liquids & semi-solids and as a solvent for parenteral formulations.
Dosage Form : Capsule, Injectable / Parenteral, Tablet
Grade : Oral, Parenteral
Category : Fillers, Diluents & Binders, Parenteral
Dosage Form : Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Softgels
Grade : Parenteral, Oral, Topical
Category : Film Formers & Plasticizers, Parenteral, Thickeners and Stabilizers, Topical
Application : Parenteral
Excipient Details : Castor oil is used as an oily solvent in parenteral dosage forms.
Global Sales Information
Company :
Clopidogrel Bisulfate
Drug Cost (USD) : 200,676,447
Year : 2022
Prescribers : 3178494
Prescriptions : 12828367
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Clopidogrel Bisulfate
Drug Cost (USD) : 7,872,337
Year : 2022
Prescribers : 3868
Prescriptions : 16661
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Clopidogrel Bisulfate
Drug Cost (USD) : 158,314,799
Year : 2021
Prescribers : 3138628
Prescriptions : 12930126
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Clopidogrel Bisulfate
Drug Cost (USD) : 8,672,716
Year : 2021
Prescribers : 4533
Prescriptions : 20038
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Clopidogrel Bisulfate
Drug Cost (USD) : 9,804,827
Year : 2020
Prescribers : 5648
Prescriptions : 26044
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Clopidogrel Bisulfate
Drug Cost (USD) : 184,677,108
Year : 2020
Prescribers : 3085966
Prescriptions : 13402749
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Clopidogrel Bisulfate
Drug Cost (USD) : 187,965,459
Year : 2019
Prescribers : 3095098
Prescriptions : 13736319
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Clopidogrel Bisulfate
Drug Cost (USD) : 11,359,796
Year : 2019
Prescribers : 6794
Prescriptions : 32487
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Clopidogrel Bisulfate
Drug Cost (USD) : 182,729,179
Year : 2018
Prescribers : 3023485
Prescriptions : 14256417
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Clopidogrel Bisulfate
Drug Cost (USD) : 13,313,914
Year : 2018
Prescribers : 8102
Prescriptions : 41233
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 1,454
2018 Revenue in Millions : 1,570
Growth (%) : -7
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 1,108
2019 Revenue in Millions : 1,614
Growth (%) : -31
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 1,023
2020 Revenue in Millions : 998
Growth (%) : 1
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 1,078
2021 Revenue in Millions : 1,023
Growth (%) : 5
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 1,023
2022 Revenue in Millions : 1,078
Growth (%) : -4
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2024 Revenue in Millions : 948
2023 Revenue in Millions : 1,023
Growth (%) : -7
Main Therapeutic Indication : Cardiovascular
Currency : USD
2014 Revenue in Millions : 0.30%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Cardiovascular
Currency : USD
2015 Revenue in Millions : 2,048
2014 Revenue in Millions : 2,122
Growth (%) : 4%
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 1,637
2015 Revenue in Millions : 2,045
Growth (%) : -20
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 1,824
2016 Revenue in Millions : 1,915
Growth (%) : -5
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
Clopidogrel Diester Enantiomer Sulfate
CAS Number :
Quantity Per Vial :
Price ($) : 1750
Catalog Number : 1A02120
Current Lot : 25 mg
Previous Lot :
NDC Code :
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
CAS Number :
Quantity Per Vial :
Price ($) : 1200
Catalog Number : 1A02110
Current Lot : 25 mg
Previous Lot :
NDC Code :
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
CAS Number : 1319197-73-3
Quantity Per Vial :
Price ($) : 1200
Catalog Number : 1A02100
Current Lot : 25 mg
Previous Lot :
NDC Code :
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
Clopidogrel Thienopyridinium Chloride
CAS Number : 2418591-11-2
Quantity Per Vial :
Price ($) : 1200
Catalog Number : 1A02080
Current Lot : 25 mg
Previous Lot :
NDC Code :
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
Clopidogrel Open Ring R-Enantiomer
CAS Number : 1258938-54-3
Quantity Per Vial :
Price ($) : 1000
Catalog Number : 1A01900
Current Lot : 25 mg
Previous Lot :
NDC Code :
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
CAS Number : 1319197-71-1
Quantity Per Vial :
Price ($) : 2000
Catalog Number : 1A01890
Current Lot : 25 mg
Previous Lot :
NDC Code :
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
CAS Number : 444728-15-8
Quantity Per Vial :
Price ($) : 800
Catalog Number : 1A01870
Current Lot : 25 mg
Previous Lot :
NDC Code :
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
CAS Number : 444728-13-6
Quantity Per Vial :
Price ($) : 840
Catalog Number : 1A01860
Current Lot : 25 mg
Previous Lot :
NDC Code :
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
Tetrahydrothienopyridine Hydrochloride
CAS Number : 28783-41-7
Quantity Per Vial :
Price ($) : 320
Catalog Number : 1A01850
Current Lot : 25 mg
Previous Lot :
NDC Code :
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
Clopidogrel Ethyl Ester Sulfate
CAS Number : 1332612-57-3
Quantity Per Vial :
Price ($) : 550
Catalog Number : 1A01730
Current Lot : 25 mg
Previous Lot :
NDC Code :
Monograph in Japanese Pharmacopoeia : Clopidogre...
Package Size : 200 mg
Price (¥) : 34,821
Storage Temperature °C : 8°C
Assay Test : I/ UV-VIS I/ IR
Monograph in Japanese Pharmacopoeia :
Package Size : 200 mg
Price (¥) : 34,821
Storage Temperature °C : 8°C
Assay Test : A/ LC
Monograph in Japanese Pharmacopoeia : Clopidogre...
Package Size : 200 mg
Price (¥) : 34,821
Storage Temperature °C : 8°C
Assay Test : U/ LC D/ UV-VIS
Monograph in Japanese Pharmacopoeia :
Package Size : 200 mg
Price (¥) : 34,821
Storage Temperature °C : 8°C
Assay Test : A/ LC
CAS Number : 1219432-42-4
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : C0007.46
CAS Number : 144750-42-5
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : C0007.01
CAS Number : 144750-52-7
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : C0007.02
CAS Number : 120202-71-3
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : C0007.03
CAS Number : 144750-42-5
Quantity Per Vial :
Sale Unit :
Price :
Details :
Monograph :
Storage :
Code/Batch No :
CAS Number : 1396841-05-6
Quantity Per Vial :
Sale Unit :
Price :
Details :
Monograph :
Storage :
Code/Batch No :
Clopidogrel Pyridinium Bromide Impurity
CAS Number : 1396607-49-0
Quantity Per Vial :
Sale Unit :
Price :
Details :
Monograph :
Storage :
Code/Batch No :
rac-Clopidogrel Carboxylic Acid Hydrochl
CAS Number : 1015247-88-7
Quantity Per Vial :
Sale Unit :
Price :
Details :
Monograph :
Storage :
Code/Batch No :
rac-Clopidogrel Hydrogen Sulfate
CAS Number : 135046-48-9
Quantity Per Vial :
Sale Unit :
Price :
Details :
Monograph :
Storage :
Code/Batch No :
S-Clopidogrel Hydrogen Sulfate
CAS Number : 120202-66-6
Quantity Per Vial :
Sale Unit :
Price :
Details :
Monograph :
Storage :
Code/Batch No :
ANALYTICAL
Product Code : AS12S05-1504WT
Classification : DrugsC Metabolites
Product Characteristics : H130716G
Category :
Description :
Product Code : AS12S05-1504WT
Classification : DrugsC Metabolites
Product Characteristics : H130704D
Category :
Description :
Product Code : AS12S05-1504WT
Classification : DrugsC Metabolites
Product Characteristics : H130711G
Category :
Description :
Product Code : TA12S05-1504WT
Classification : DrugsC Metabolites
Product Characteristics : U120517E
Category :
Description :
ABOUT THIS PAGE
19
PharmaCompass offers a list of Clopidogrel API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Clopidogrel manufacturer or Clopidogrel supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Clopidogrel manufacturer or Clopidogrel supplier.
PharmaCompass also assists you with knowing the Clopidogrel API Price utilized in the formulation of products. Clopidogrel API Price is not always fixed or binding as the Clopidogrel Price is obtained through a variety of data sources. The Clopidogrel Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate, including repackagers and relabelers. The FDA regulates Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate supplier is an individual or a company that provides Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate active pharmaceutical ingredient (API) or Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate finished formulations upon request. The Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate suppliers may include Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate API manufacturers, exporters, distributors and traders.
click here to find a list of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate DMF (Drug Master File) is a document detailing the whole manufacturing process of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate active pharmaceutical ingredient (API) in detail. Different forms of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate DMFs exist exist since differing nations have different regulations, such as Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate DMF submitted to regulatory agencies in the US is known as a USDMF. Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate USDMF includes data on Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate Drug Master File in Japan (Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate JDMF) empowers Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate JDMF during the approval evaluation for pharmaceutical products. At the time of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate Drug Master File in Korea (Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate. The MFDS reviews the Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate KDMF as part of the drug registration process and uses the information provided in the Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate suppliers with KDMF on PharmaCompass.
A Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate CEP of the European Pharmacopoeia monograph is often referred to as a Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate Certificate of Suitability (COS). The purpose of a Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate to their clients by showing that a Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate CEP has been issued for it. The manufacturer submits a Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate CEP holder for the record. Additionally, the data presented in the Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate DMF.
A Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate suppliers with CEP (COS) on PharmaCompass.
A Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate written confirmation (Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate WC) is an official document issued by a regulatory agency to a Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate manufacturer, verifying that the manufacturing facility of a Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate APIs or Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate finished pharmaceutical products to another nation, regulatory agencies frequently require a Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate WC (written confirmation) as part of the regulatory process.
click here to find a list of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate suppliers with NDC on PharmaCompass.
Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate GMP manufacturer or Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate GMP API supplier for your needs.
A Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate CoA (Certificate of Analysis) is a formal document that attests to Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate's compliance with Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate specifications and serves as a tool for batch-level quality control.
Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate CoA mostly includes findings from lab analyses of a specific batch. For each Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate may be tested according to a variety of international standards, such as European Pharmacopoeia (Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate EP), Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Clopidogrel Hemisulfate, Iscover, Myogrel, Plavix,Clopidogrel bisulfate USP).